Sanofi, Sobi Earlier Announced ALTIVIIIO Late-breaking Data At ISTH Demonstrates Highly Effective Bleed Protection In Children With Severe Hemophilia A With Once-weekly Dosing
Portfolio Pulse from Charles Gross
Sanofi and Sobi announced positive results from the Phase 3 XTEND-Kids study of ALTUVIIIO, a first-in-class, high-sustained factor VIII replacement therapy for children with severe hemophilia A. The study met its primary endpoint with no inhibitor development to factor VIII detected and key secondary endpoints.
June 26, 2023 | 12:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sobi's ALTUVIIIO showed positive results in Phase 3 XTEND-Kids study for children with severe hemophilia A, potentially leading to increased interest in the company's stock.
The positive results from the Phase 3 XTEND-Kids study indicate that ALTUVIIIO is effective in treating children with severe hemophilia A. This could lead to increased interest in Sobi's stock as the company moves closer to potentially bringing the treatment to market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Sanofi's collaboration with Sobi on ALTUVIIIO, which showed positive results in a Phase 3 study for children with severe hemophilia A, may positively impact the company's stock.
Sanofi's collaboration with Sobi on the development of ALTUVIIIO, which has shown positive results in a Phase 3 study for children with severe hemophilia A, may lead to increased interest in the company's stock. The successful development of the treatment could strengthen Sanofi's position in the hemophilia market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50